Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies Third Arc Bio has successfully raised $52 million in a Series A funding extension, aiming to boost its oncology and immunology portfolio with groundbreaking therapies.

Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies #United_States #Spring_House #oncology #Immunology #Third_Arc_Bio